Erythropoiesis-stimulating agents (ESAs)
Title
Date Published
Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
November 30, 2008
Recombinant Human Erythropoietin Therapy in Critically Ill Jehovah’s Witnesses.
November 1, 2008
Atorvastatin increases erythropoietin- stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
October 31, 2008
Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
September 29, 2008
Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
September 15, 2008
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.
August 29, 2008
The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions
August 1, 2008
Pre-operative injections of epoetin-{alpha} versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: A PROSPECTIVE RANDOMISED CLINICAL TRIAL.
August 1, 2008
Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
July 31, 2008
Anemia and erythropoietin in heart failure.
June 30, 2008
New erythropoiesis-stimulating agents: how innovative are they?
June 30, 2008
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
June 30, 2008
Stimulating Erythropoiesis: Future Perspectives.
June 28, 2008
Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
June 1, 2008
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
May 31, 2008
Urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants.
May 1, 2008
Developments in the therapeutic use of erythropoiesis stimulating agents.
May 1, 2008
Erythropoietins should be used according to guidelines.
May 1, 2008
Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
May 1, 2008
Thrombosis with Erythropoietic Stimulating Agents – Does Iron-Deficient Erythropoiesis Play a Role?
April 6, 2008